Compare CVS Health Corp (CVS) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Fox Corp Class A — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Fox Corp Class A trades at $63.88 (market cap $24.97B). The key difference: CVS Health Corp is far larger — about 4.5× Fox Corp Class A's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Fox Corp Class A for 34 Days on average.
| CVS | FOXA | |
|---|---|---|
Market Cap | $112.49B | $24.97B |
Volume | 8,467,392 | 4,070,311 |
Sector | Health | Media |
52-Week High | $110.60 | $76.11 |
52-Week Low | $70.08 | $48.79 |
Typical Hold Time | 83 Days | 34 Days |
Enterprise Value | $174.83B | $28.33B |
Dividend Yield | 3.02% | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
FOXA trades at $62.70, up 1.0% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $1.79 beating expectations by 24%. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. The pending $22B Roku acquisition faces extended DOJ review, creating regulatory uncertainty while CEO Lachlan Murdoch recently purchased $10.3M in shares.
FOXA presents a compelling value case with attractive valuation multiples (P/E 16.33, P/S 1.61) and strong profitability (ROE 14.29%). Analyst consensus targets $72.00 with 52% buy ratings, offering 15% upside potential. Key risks include regulatory hurdles for the Roku deal and projected 2026 margin compression. The stock's current technical weakness may provide entry opportunity for fundamental investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
